
Tailored remote support may help breast cancer survivors with low self-efficacy
AI-summarized from the linked source. Educational brief, not medical advice.
Brief summary
A post hoc randomized-trial analysis found lower symptom-management self-efficacy identified breast cancer survivors with poorer outcomes who appeared to benefit most from remote monitoring plus tailored messages.
What NurseJet pulled from the source
The analysis included 264 women prescribed adjuvant endocrine therapy and compared enhanced usual care, weekly app monitoring, and app monitoring plus tailored supportive texts. Higher baseline self-efficacy was associated with lower symptom burden and greater adherence. At a low self-efficacy score of 30, estimated adherence was 52.7% with app plus feedback versus 17.8% with usual care, but the confidence interval was wide and the subgroup analysis was post hoc.
Why this matters for nurses
Endocrine-therapy symptoms and low confidence managing them can undermine long-term treatment. Oncology nurses can identify support needs, normalize symptom reporting, and close the loop with the oncology team while recognizing that an app is an adjunct rather than a replacement for care.
Bedside takeaway
Low confidence managing endocrine-therapy symptoms can be a cue for more tailored follow-up and adherence support.
How This Applies in Practice
Use this when: Following a breast cancer survivor who is taking adjuvant endocrine therapy and reports symptoms, missed doses, or low confidence managing treatment.
On your shift
- Assess symptom burden, self-management confidence, missed doses, access barriers, and the patient's preferred method of follow-up.
- Use teach-back for the prescribed regimen and explain how and when to report symptoms through the approved remote or clinic pathway.
- Escalate persistent symptoms, adherence barriers, or treatment concerns to the oncology team for individualized management.
Key takeaways
- The post hoc analysis included 264 women from a randomized trial of app-based symptom and adherence monitoring.
- Higher baseline symptom-management self-efficacy was associated with lower symptom burden and greater odds of endocrine-therapy adherence.
- The tailored-feedback intervention showed its largest estimated adherence benefit at lower self-efficacy levels.
- The low-self-efficacy estimate had a wide confidence interval, and effects diminished and became nonsignificant at higher self-efficacy levels.
Practice implications
- Ask how confident the patient feels managing symptoms and the daily regimen, then assess barriers, symptom burden, missed doses, and support preferences. Route concerns through the survivorship or oncology pathway and use remote monitoring only within the approved program.
Limitations & cautions
- This was a post hoc effect-modification analysis rather than a prespecified primary comparison. Adherence was recorded with a connected pillbox, the low-self-efficacy estimate was imprecise, and the findings do not establish that the same intervention will work in other populations or platforms.
- AI-summarized from the linked source. Review the original article before applying to practice.
Citations
Exact source links
Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.
The American journal of managed care (PubMed)
The American journal of managed care (PubMed). Remote Monitoring and Self-Efficacy: Implications for Breast Cancer Survivorship Outcomes.
https://pubmed.ncbi.nlm.nih.gov/42663546/
Professional education only


